Traffic Lights - Latest Updates

Last updated: 05/09/2022

Other updates on this site
Drug Name Classification Clinical Indication Comments
ALPROSTADIL uretheral sticks and injections Green Erectile dysfunction

Only prescribable under the NHS for treatment of erectile dysfunction in men who meet the criteria listed in part XVIIIB of the Drug Tariff. The prescription must be endorsed ‘SLS’.

Maximum 4 doses per month to be prescribed.
MUSE transurethral sticks have been temporarily discontinued. Intracavernous injections remain available. 
ANIDULAFUNGIN Red Invasive candidiasis
BUDESONIDE/ FORMOTEROL FUMARATE DIHYDRATE INHALER (GoResp Digihaler®) Do not prescribe

Discontinued June 2024 – see MHRA alert
EFANESOCTOCOG ALFA (NEW) Red Treating and preventing bleeding episodes in haemophilia A in people 2 years and over

Funding from 02/07/2025

NICE TA1051
ENOXAPARIN Green Thromboprophylaxis and treatment of DVT and PE

Prescribe by brand name INHIXA® as different brands have different injection techniques.

Courses started during the dalteparin shortage can be continued to be supplied in primary care
ESZOPICLONE (Lunivia) (NEW) Do not prescribe

Not approved for use in LLR.
FOSLEVODOPA/FOSCARBIDOPA (NEW) Red Advanced Parkinson’s with motor symptoms

Funding from when SCA with NUH as specialist neurology centre approved by NHSE

NICE TA934
LANDIOLOL (Rapibloc) (NEW) Red Management of AF in level 2 clinical areas.
MOMETASONE/ OLOPATADINE NASAL SPRAY (Ryaltris ®) (UPDATED) Green Moderate to severe nasal symptoms associated with allergic rhinitis

Third line choice in line with local allergic rhinitis pathway.
MORPHINE SULPHATE (Actimorph orodispersible tablets) (NEW) Green Use within palliative care to avoid escalation to subcutaneous preparations particularly in patients with impaired swallow and/or intestinal absorption

New formulation (May 2025).
PALOPEGTERIPARATIDE (Yorvipath) Grey

Review deferred pending NICE outcome.
REZAFUNGIN Red Invasive candidiasis
RITLECITINIB (Litfulo) Red Severe alopecia areata in people 12 years and over

In line with NICE TA 958.

 
RITUXIMAB Red IgM paraproteinaemic demyelinating peripheral neuropathy in adults
Tixagevimab plus Cilgavimab Do not prescribe

Not recommended, within its marketing authorisation, for treating COVID‑19 as per NICE TA971.
USTEKINUMAB Red For refractory Crohn’s disease in pre-pubescent children (aged < 6 years old)

In line with NHSE Clinical Commissioning Policy.
VADADUSTAT (NEW) Red Aymptomatic anaemia in adults having dialysis for chronic kidney disease

Funding from 23/04/2025

NICE TA1035

Other Updates on this Website

Recent documents from LLR APC and TAS

About the Leicester, Leicestershire and Rutland Area Prescribing Committee

In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more